Capital raising for quantitative and systematic funds
The pitch is a model, not a person — which means allocators diligence the process of building it, not just its output.
Quantitative and systematic funds present a specific diligence problem: the strategy's real edge often lives inside proprietary code an allocator will never see in full, so trust has to be built through process transparency rather than model transparency. The two questions every serious quant allocator brings are whether the backtest is overfit, and whether live performance has actually tracked what the backtest promised.
The overfitting problem
Any sufficiently flexible model can be tuned to produce an excellent backtest on historical data — that is not evidence of a real edge, it is evidence of enough free parameters and enough trial and error. Sophisticated allocators know this, and they probe specifically for it: how many strategies were tested before this one was chosen, what the out-of-sample and walk-forward validation looked like, whether the research process was pre-registered or iteratively fit to the same dataset, and how the model's assumptions were stress-tested outside the historical sample it was built on.
The live-versus-backtest gap
The single most useful piece of evidence a quant manager can offer is a clean comparison of live, real-money performance against what the pre-launch backtest predicted for the same period. A close match is powerful evidence the research process is sound. A meaningful gap — even if live performance is still positive — demands an honest explanation: was it slippage, capacity constraints, a regime the backtest didn't cover, or does it suggest the original backtest was overfit after all? Allocators trust managers who volunteer this comparison unprompted far more than those who present only backtested figures dressed up as a track record.
What allocators diligence
- Research process and governance. How new signals are discovered, validated and approved for live trading — and whether that process is documented and repeatable, not ad hoc.
- Data and execution infrastructure. Data cleaning, survivorship-bias handling, transaction cost modelling, and whether backtests reflect realistic execution rather than idealised fills.
- Capacity and crowding. Quant strategies frequently degrade sharply with AUM as signals get arbitraged away or become too large to execute without moving markets. A specific, reasoned capacity estimate is expected, not optional.
- Model risk management. What happens when a model's live performance diverges from its expected statistical behaviour — kill switches, position limits, human override authority.
- Team and key-person risk. Whether the research process depends on one person's intuition or is genuinely institutionalised across a team, since a departure is far more damaging to a strategy built around one researcher's proprietary insight.
- Technology and cybersecurity. Infrastructure resilience, disaster recovery, and controls around code and data access — this receives unusually close attention in quant operational due diligence specifically.
| Sub-style | What allocators focus on |
|---|---|
| Statistical arbitrage | Signal decay, crowding, execution cost modelling realism |
| Trend-following / CTA | Performance across different volatility regimes, correlation to other CTAs |
| Market-making / high-frequency | Technology infrastructure, latency, regulatory and venue relationships |
| Factor-based / risk premia | Genuine differentiation from well-known academic factors versus repackaging them at a fee |
How to raise capital as a quant manager
Lead with the live-vs-backtest comparison
Volunteering this before being asked is the single strongest credibility signal available to a systematic manager.
Explain the research process, not just the output
Allocators are underwriting your ability to keep finding edges, not just the one you have today. Show how new signals get discovered and validated.
Give a specific, reasoned capacity number
State the AUM at which you expect degradation and why, tied to the liquidity of what you actually trade.
Address key-person risk directly
If the research process depends heavily on one person, say so and explain what mitigates it — don't let an allocator discover it in reference calls.
Be ready for a technology and infrastructure review
Quant operational due diligence goes deeper on technology, data handling and cybersecurity than almost any other strategy.
Frequently asked questions
What is overfitting and why do allocators care?
What is the live-versus-backtest gap?
How much capacity does a quantitative strategy have?
What is walk-forward validation?
Why does key-person risk matter more for some quant funds than others?
What does operational due diligence focus on for a quant fund?
Nothing on this page is legal, tax, or investment advice. SeRuM is not a registered broker-dealer, not a placement agent, and not an investment adviser.
Next step
Tell us what you're raising.
Entity type, target size, timeline. That's enough for us to tell you quickly whether we can help — and to say so plainly if we can't.